95 related articles for article (PubMed ID: 2300389)
1. Concomitant administration of 4-hydroxypyrazolopyrimidine (allopurinol) and high-dose continuous infusion 5-fluorouracil.
Tsavaris N; Karagiaouris P; Vonorta K; Bacogianis H; Milonakis N; Karvounis N; Kakoliris S; Zepou E; Karabelis A; Papazahariou M
Oncology; 1990; 47(1):70-4. PubMed ID: 2300389
[TBL] [Abstract][Full Text] [Related]
2. A controlled trial of the effect of 4-hydroxypyrazolopyrimidine (allopurinol) on the toxicity of a single bolus dose of 5-fluorouracil.
Woolley PV; Ayoob MJ; Smith FP; Lokey JL; DeGreen P; Marantz A; Schein PS
J Clin Oncol; 1985 Jan; 3(1):103-9. PubMed ID: 3965628
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of high-dose continuous infusion 5-fluorouracil with allopurinol modulation in colon cancer.
Ahmann FR; Garewal H; Greenberg BR
Oncology; 1986; 43(2):83-5. PubMed ID: 3951789
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
5. 5-Fluorouracil and methotrexate administered simultaneously as a continuous infusion. A phase I study.
Lokich JJ; Phillips D; Green R; Paul S; Sonneborn H; Zipoli TE; Curt G
Cancer; 1985 Nov; 56(10):2395-8. PubMed ID: 4042072
[TBL] [Abstract][Full Text] [Related]
6. Weekly high-dose infusional 5-fluorouracil (HD-5-FU) combinations in the treatment of advanced breast cancer: results of phase I/II studies with weekly 24-hour infusion of HD-5-FU plus high-dose folinic acid (FA) alone and in combination with paclitaxel and cisplatin.
Klaassen U; Wilke H; Seeber S
J Infus Chemother; 1996; 6(3):127-32. PubMed ID: 9229323
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
[TBL] [Abstract][Full Text] [Related]
8. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Greenblatt MS; Mangalik A; Ferguson J; Elias L
Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
[TBL] [Abstract][Full Text] [Related]
9. Continuous 24-hour infusion of folinic acid does not increase the response rate of 5-fluorouracil but only the toxicity.
Tsavaris N; Tzannou I; Karvounis N; Kosmidis P
Oncology; 1992; 49(2):154-6. PubMed ID: 1574252
[TBL] [Abstract][Full Text] [Related]
10. Failure of allopurinol to provide clinically significant protection against the hematologic toxicity of a bolus 5-FU schedule.
Garewal H; Ahmann FR
Oncology; 1986; 43(4):216-8. PubMed ID: 3725283
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
[TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
[TBL] [Abstract][Full Text] [Related]
13. Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer.
Klaassen U; Harstrick A; Wilke H; Seeber S
Semin Oncol; 1996 Feb; 23(1 Suppl 1):44-7. PubMed ID: 8629037
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study of a combination of cisplatin (DDP), 5-fluorouracil (5-FU), and allopurinol (HPP) versus 5-FU in advanced colorectal carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group study.
Bleiberg H; Vanderlinden B; Buyse M; Haegele P; Paillot B; Tagnon A; Wils J; Cartei G; Fornasiero A; Duez N
Cancer Invest; 1990; 8(5):471-5. PubMed ID: 2265371
[TBL] [Abstract][Full Text] [Related]
15. A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.
Forastiere AA; Natale RB; Takasugi BJ; Goren MP; Vogel WC; Kudla-Hatch V
J Clin Oncol; 1987 Feb; 5(2):190-6. PubMed ID: 3543242
[TBL] [Abstract][Full Text] [Related]
16. Effect of allopurinol on the toxicity of high-dose 5-fluorouracil administered by intermittent bolus injection.
Howell SB; Pfeifle CE; Wung WE
Cancer; 1983 Jan; 51(2):220-5. PubMed ID: 6336975
[TBL] [Abstract][Full Text] [Related]
17. [Low-dose CDDP and 5-FU for head and neck cancer patients].
Fujii M; Kanke M; Tomita T
Gan To Kagaku Ryoho; 1999 Oct; 26(11):1542-7. PubMed ID: 10553410
[TBL] [Abstract][Full Text] [Related]
18. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević A
Srp Arh Celok Lek; 1998; 126(9-10):355-61. PubMed ID: 9863407
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion.
Remick SC; Grem JL; Fischer PH; Tutsch KD; Alberti DB; Nieting LM; Tombes MB; Bruggink J; Willson JK; Trump DL
Cancer Res; 1990 May; 50(9):2667-72. PubMed ID: 2328492
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG
Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
